IMR Press / FBL / Volume 8 / Issue 6 / DOI: 10.2741/943

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Clinical aspects of allergic bronchopulmonary aspergillosis
Show Less
1 Division of Allergy-Immunology and the Ernest S. Bazley Asthma and Allergic Diseases Center, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Academic Editor: Viswanath Kurup

Front. Biosci. (Landmark Ed) 2003, 8(6), 119–127;
Published: 1 January 2003
(This article belongs to the Special Issue Allergic aspergillosis)

Allergic Bronchopulmonary Aspergillosis (ABPA) is characterized by recurrent pulmonary infiltrates that can result in central bronchiectasis and bronchiolitis obliterans especially if there is a lack of recognition and treatment. The incidence of ABPA is 1-2% in patients with persistent asthma and approximately 7% (range 2-15) in patients with cystic fibrosis. The diagnostic criteria are useful in that there is no single test (with the exception of central bronchiectasis in patients with asthma) that identifies ABPA. The differential diagnosis of ABPA includes many conditions including chronic eosinophilic pneumonia, Churg Strauss Syndrome, Hyper-IgE Syndrome, persistent asthma with lobar collapse, and cases of parasitism. The most useful laboratory assays in patients who have immediate cutaneous reactivity. to Aspergillus mixes or A. fumigatus are total serum IgE concentration, elevated serum IgE-A.fumigatus and serum IgG-A.fumigatus. Prednisone remains the drug of choice yet need not be administered indefinitely.

Allergic Bronchopulmonary Aspergillosis
Back to top